Lyon, France — genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today reports an important framework agreement with Beth Israel Deaconess Medical Center (BIDMC) Harvard Medical School’s Teaching Hospital located in Boston (USA). The National Institute of Health (NIH) ranks BIDMC as the 4th best independent Teaching Hospital of the United States.

In spite of a competition with several international companies, BIDMC has finally decided to opt for genOway to conclude a framework agreement of a two years renewable period. The financial terms of the agreement were not disclosed.

With this partnership, researchers of BIDMC whose prestigious areas of study cover metabolic diseases, cardiology, neurobiology and infectious diseases including AIDS, will benefit from the expertise gained by genOway in transgenic technology and technological innovations developed by the Company, such as inducible systems that secure and accelerate the development of sophisticated genetically modified models of mice and rats.

Alexandre Fraichard, CEO of genOway, declared: « After an international competition, we have been chosen to supply BIDMC, Harvard Medical School’s prestigious Teaching Hospital with genetically modified rodents. We are very proud to provide our proprietary technologies to scientists working on such ambitious and important topics for human health such as AIDS or cancerology. For genOway, the contract takes part in the 2009 commercial dynamic that we announced in early November, after the last framework agreement established with the University of Pennsylvania (Upenn). In accordance with our goals and prospects, we continue to sign partnerships with major innovation actors that provide a solid base for our recipient economic growth in 2010 and 2011.»

About BIDMC The Beth Israel Deaconess Medical Center (BIDMC) Harvard Medical School’s Teaching Hospital is ranked according to the National Institute of Health’s (NIH) classification as the 4th best independent Teaching Hospital of the United States. It distinguishes itself with a strong overlapping of its scientific and clinical teams. BIDMC’s prestigious areas of study are metabolic disorders, neurobiology, infectious diseases, including AIDS and cardiology. More than 850 research projects are funded by agencies like the NIH or the National Science Foundation (NSF) and over 500 clinical trials of all specialties are being conducted within the center. For more information please go to www.bidmc.org

About genOway genOway (ALTERNEXT-NYSE: ALGEN) is a biotechnology company developing genetically modified and high value-added research models for the bio-pharmaceutical, chemical, agrochemical and food industry as well as for academic research. With highly qualified scientific personnel, the company has a work force of 60 people and operates in over 22 countries in Europe, Asia and North America, supplying more than 285 research institutes and bio-pharmaceutical companies. genOway is a leader in its market in terms of both size and customer portfolios. The company’s development is founded upon both a broad and exclusive technology platform as well as strong intellectual property rights combining patents and licensing agreements. Taking advantage of the global trend towards outsourcing the production of genetically modified research models, genOway has signed many contracts with leaders of the pharmaceutical industry (Pfizer, Bayer, Boehringer Ingelheim, etc.), and with the most prestigious academic research centers (King’s College and the University of Manchester, in England; Duke University and the National Institutes of Health, in the United States; the Institut Pasteur, in France; NGFN and the Max Planck Institutes, in Germany, etc.).

To strengthen its technological position and benefit from worldwide business partners, genOway has signed strategic alliances with leading companies in their field: Charles River Laboratories (NYSE: CRL, a world leader in supplying laboratory animals), Invitrogen (NASDAQ: IVGN, world leader in supplying molecular biology reagents). For more information please go to www.genoway.com.

Warning: This press release contains certain prospective statements, either express or implied, concerning genOway and its activities. These statements rely on certain risks, either known or unknown, uncertainties or other factors, that may lead to genOway’s actual results, financial condition, performance or achievements differing significantly from the results, financial condition, performance or achievements expressed or implied in these prospective statements. genOway is issuing this press release on the present date and is not committed to updating the prospective statements contained therein, either as a result of new information, future events or any other occurrence. For a detailed description of the types of risks or uncertainties likely to cause a difference between genOway’s actual results, financial condition, performance or achievements and those contained in the prospective statements, please refer to the section on “Risk Factors” in the prospectus available on the genOway website: www.genoway.com.